|
Journal
of Advancement in Medicine
Volume 6, Number 3, Fall 1993
Benefits of EDTA Chelation Therapy in Arteriosclerosis: A Retrospective
Study of 470 Patients.
C.
Hancke, M.D, and K. Flytlie, M.D.
Abstract:
In a retrospective study we report results of EDTA chelation in 470
patients, using a number of parameters, most of them objective. Although
the patients acted as their own controls, we observed improvements of 8O
to 91%, depending on the measurement used. Of 92 patients referred for
surgical intervention, only 10 required ultimate surgery after or during
their chelation therapy, thus saving an estimated 3 million dollars of
insurance money. Our experience covers a period of 6 years and we saw no
severe side effects or casualties arising from the treatment. We
conclude that EDTA chelation therapy is safe effective and cost saving.
Introduction:
Intravenous administration of ethylene diamine tetraacetic acid (EDTA)
has been used from the beginning of the 1950's by an increasing number
of physicians throughout the world for the treatment of
arteriosclerosis. In the last few years, there has been
increasing criticism of surgical intervention in this disease, since it
falls to prolong life, and is a temporary solution in treating a
generalized, chronic condition (1). In addition, surgery damages vital
tissue by means of reperfusion-released free radical bursts (2,3).
Effective- ness of EDTA chelation therapy is cumulative over many years
(4,90), and the recent association of iron in the etiology of
cardiovascular disease (IO) makes the technique worthy of complete
acceptance today.
Claus Hancke, M.D. received his medical education at the University of
Copenhagen. He is in general practice and is the president of the Danish
Chelation Doctors. He is an ABCT diplomat.
Knut
Flytlie, M.D. received his medical education at the University of
Gutenberg, Germany. He is in general practice and operates a clinic for
Preventive Medicine and Chelation. He is an ABCT diplomat.
Address correspondence to Claus Hancke, M. D.,Hovedgade 17, 1, DK-
2800-LYNGBY, Denmark. Additional information may be obtained from ACAM.
Phone number on contents page.
*In our view, the beneficial results that
were observed were far in excess of the 10-15% improvement that is
usually seen in the placebo group of a controlled study. Of 65 patients
who were referred for coronary by-pass surgery, 58 did not require it
after chelation therapy. |
